Stephen Aherne, pharmaceuticals and life sciences leader, PwC UK said:
“It is welcome news that a deal has been reached, as part of the UK-US drug tariff negotiations, to address concerns with the UK commercial model around drug pricing.
“As anticipated, the National Institute for Health and Care Excellence (NICE) cost effectiveness thresholds are to be increased. It's a threshold that has somehow avoided any inflationary increase since it was brought into being. Although, it will take time to filter through into new medicines, at its core, it means that more innovative and rare disease medicines will be available to UK patients in the coming years, which can only be a good thing.
“This change, alongside the adjusted VPAG rebate cap of 15% for the remaining life of the scheme, and the 0% tariff on UK imported medicines into the US, demonstrates a more supportive stance towards a hugely strategic sector for the UK economy.”
About PwC
At PwC, we help clients build trust and reinvent so they can turn complexity into competitive advantage. We’re a tech-forward, people-empowered network with more than 364,000 people in 136 countries and 137 territories. Across audit and assurance, tax and legal, deals and consulting, we help clients build, accelerate, and sustain momentum. Find out more at pwc.com.
© 2026 PwC. All rights reserved.
